John Westwater

Bio

Joined Phase4 Ventures in 2004. Prior to this, spent over four years at Morgan Stanley within their Healthcare Investment Banking Group and Mergers, Acquisitions and Restructuring Department (MARD). During this time, advised a number of pharmaceutical and biotechnology companies including Elan on its successful recovery and restructuring plan that resulted in asset divestment proceeds of more than $2 billion. Was also heavily involved in several capital market offerings including Elan's concurrent convertible bond and equity offering in 2003 and Epigenomics' IPO in 2004. Since joining Phase4 Ventures, has been involved with investments in Cerimon, Zosano and Atani and he is also involved with managing the sale of stock in public portfolio companies. PhD and a BSc (Hons) in Biochemistry from Heriot-Watt University.